An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer

An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer

A wide inter-individual variability in the therapeutic response to cyclin-dependent kinases 4 and 6 inhibitors (CDKis) has been reported. We herein present a case series of five patients treated with either palbociclib or ribociclib referred to our clinical pharmacological counselling, including the...

Full description

Bibliographic Details
Main Authors: Rossana Roncato, Lorenzo Gerratana, Lorenza Palmero, Sara Gagno, Ariana Soledad Poetto, Elena Peruzzi, Martina Zanchetta, Bianca Posocco, Elena De Mattia, Giovanni Canil, Martina Alberti, Marco Orleni, Giuseppe Toffoli, Fabio Puglisi, Erika Cecchin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Pharmacology
Subjects:
personalized medicine
TDM
polymorphisms
pharmacological counselling
breast cancer
CDK4/6 inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.897951/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.897951/full

Similar Items